Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
| ▸ | AHCY | P23526 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.36 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14440197 | 1.00 | HIF1A (0.39) | HIF1ATYMPAHCYPOLBENPP1 | |
| SCHEMBL14568433 | 1.00 | HIF1A (0.39) | HIF1ATYMPAHCYPOLBENPP1 | |
| SCHEMBL14440555 | 1.00 | HIF1A (0.39) | HIF1ATYMPAHCYPOLBENPP1 | |
| SCHEMBL14440950 | 1.00 | HIF1A (0.39) | HIF1ATYMPAHCYPOLBENPP1 | |
| SCHEMBL14440608 | 1.00 | HIF1A (0.39) | HIF1ATYMPAHCYPOLBENPP1 | |
| SCHEMBL14440560 | 0.94 | HIF1A (0.37) | HIF1ATYMPAHCYPOLBENPP1 | |
| SCHEMBL14440650 | 0.87 | ADORA3 (0.37) | HIF1ATYMPAHCYEHMT1ADORA3 | |
| SCHEMBL14440925 | 0.82 | TYMP (0.42) | TYMPAHCYEHMT1ADORA3 | |
| SCHEMBL14440209 | 0.81 | TYMP (0.50) | TYMPAHCYEHMT1ADORA3 | |
| SCHEMBL14440206 | 0.81 | TYMP (0.36) | TYMPAHCYEHMT1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | IDENIX PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007025043-A2 | SEVEN-MEMBERED RING NUCLEOSIDES | IDENIX PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | NSUN2, NSUN3, HAVCR2 | HIF1A 3398/4885TYMP 148/4885AHCY 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.